These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 16420078)

  • 1. Residual symptoms in depressed patients after treatment with fluoxetine or reboxetine.
    Nelson JC; Portera L; Leon AC
    J Clin Psychiatry; 2005 Nov; 66(11):1409-14. PubMed ID: 16420078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are there differences in the symptoms that respond to a selective serotonin or norepinephrine reuptake inhibitor?
    Nelson JC; Portera L; Leon AC
    Biol Psychiatry; 2005 Jun; 57(12):1535-42. PubMed ID: 15953490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder.
    Versiani M; Mehilane L; Gaszner P; Arnaud-Castiglioni R
    J Clin Psychiatry; 1999 Jun; 60(6):400-6. PubMed ID: 10401920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reboxetine versus fluoxetine: an overview of efficacy and tolerability.
    Massana J
    J Clin Psychiatry; 1998; 59 Suppl 14():8-10. PubMed ID: 9818624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression.
    Andreoli V; Caillard V; Deo RS; Rybakowski JK; Versiani M
    J Clin Psychopharmacol; 2002 Aug; 22(4):393-9. PubMed ID: 12172339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine.
    Fava M; McGrath PJ; Sheu WP;
    J Clin Psychopharmacol; 2003 Aug; 23(4):365-9. PubMed ID: 12920412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning.
    Dubini A; Bosc M; Polin V
    J Psychopharmacol; 1997; 11(4 Suppl):S17-23. PubMed ID: 9438229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the effectiveness of reboxetine versus fluoxetine in patients with atypical depression: a single-blind, randomized clinical trial.
    Taner E; Demir EY; Cosar B
    Adv Ther; 2006; 23(6):974-87. PubMed ID: 17276965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine.
    Baldwin D; Bridgman K; Buis C
    J Psychopharmacol; 2006 Jan; 20(1):91-6. PubMed ID: 16204325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do noradrenaline and serotonin differentially affect social motivation and behaviour?
    Dubini A; Bosc M; Polin V
    Eur Neuropsychopharmacol; 1997 Apr; 7 Suppl 1():S49-55; discussion S71-3. PubMed ID: 9169310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder.
    Versiani M; Cassano G; Perugi G; Benedetti A; Mastalli L; Nardi A; Savino M
    J Clin Psychiatry; 2002 Jan; 63(1):31-7. PubMed ID: 11838623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chairman's overview. The place of reboxetine in antidepressant therapy.
    Montgomery SA
    J Clin Psychiatry; 1998; 59 Suppl 14():26-9. PubMed ID: 9818628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of antidepressant use on social functioning: reboxetine versus fluoxetine.
    Venditti LN; Arcelus A; Birnbaum H; Greenberg P; Barr CE; Rowland C; Williamson T
    Int Clin Psychopharmacol; 2000 Sep; 15(5):279-89. PubMed ID: 10993130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of reboxetine on major depressive disorder in breast cancer patients: an open-label study.
    Grassi L; Biancosino B; Marmai L; Righi R
    J Clin Psychiatry; 2004 Apr; 65(4):515-20. PubMed ID: 15119914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of reboxetine on Hamilton Depression Rating Scale factors from randomized, placebo-controlled trials in major depression.
    Ferguson JM; Mendels J; Schwart GE
    Int Clin Psychopharmacol; 2002 Mar; 17(2):45-51. PubMed ID: 11890185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.
    Davidson JR; Meoni P; Haudiquet V; Cantillon M; Hackett D
    Depress Anxiety; 2002; 16(1):4-13. PubMed ID: 12203668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluoxetine treatment of depressed patients with comorbid anxiety disorders.
    Sonawalla SB; Farabaugh A; Johnson MW; Morray M; Delgado ML; Pingol MG; Rosenbaum JF; Fava M
    J Psychopharmacol; 2002 Sep; 16(3):215-9. PubMed ID: 12236627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder.
    Massana J; Möller HJ; Burrows GD; Montenegro RM
    Int Clin Psychopharmacol; 1999 Mar; 14(2):73-80. PubMed ID: 10220121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of reboxetine on depression in Parkinson's disease patients.
    Lemke MR
    J Clin Psychiatry; 2002 Apr; 63(4):300-4. PubMed ID: 12000202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy of reboxetine in major depression.
    Schatzberg AF
    J Clin Psychiatry; 2000; 61 Suppl 10():31-8. PubMed ID: 10910015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.